PC
LRMR icon

Pier Capital’s Larimar Therapeutics LRMR Stock Holding History

Pier Capital’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-14,032
Closed -$6.67M – 122
2015
Q1 		$6.67M Buy
+14,032
New +$6.66M 1% 53

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Janus Henderson Investors US
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Pier Capital's LRMR Position: Q2 2015 in Review

Pier Capital sold out of Larimar Therapeutics (LRMR) in Q2 2015, closing a stake of 14,032 shares — an estimated $6.67M sold.

Pier Capital first reported a position in LRMR in Q1 2015 and held it in 1 quarter. The position peaked at $6.67M in Q1 2015. 89 funds tracked by Wall St. Rank hold LRMR as of Q2 2015.

  • Pier Capital reported no remaining Larimar Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Pier Capital sold 14,032 Larimar Therapeutics shares in Q2 2015, an estimated $6.67M.
  • Pier Capital first reported a position in Larimar Therapeutics in Q1 2015 and held it in 1 quarter.
  • Pier Capital's Larimar Therapeutics position peaked at $6.67M in Q1 2015.
  • 89 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2015.

Based on Pier Capital's 13F filing for Q2 2015, filed 12 Aug 2015.